Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Oncology and palliative care indexChapter sections
Purpose and principlesIndications, selection and cautionsAssessment before treatmentTreatment approachRegimens, contraindications and interactionsComplications, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook10 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Cytotoxic chemotherapy

Oncology and palliative care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Fever or clinical deterioration during or after systemic anticancer treatment is neutropenic sepsis until assessed. Arrange immediate hospital evaluation, full blood count, cultures and protocol-led intravenous antibiotics without waiting for neutrophil confirmation. Also escalate anaphylaxis, chest pain, severe diarrhoea, uncontrolled vomiting, bleeding, confusion, oliguria and suspected extravasation.

Purpose and principles

Explain how cytotoxic regimens are selected and delivered, verify treatment safety before every cycle, prevent dosing and route errors, and respond rapidly to neutropenic sepsis and organ-specific toxicity.

Cytotoxic chemotherapy can be curative, neoadjuvant, adjuvant or palliative. Cell kill often relates to dose and schedule, but normal marrow, gastrointestinal mucosa, hair follicles and gonads are also affected. Combination regimens balance non-overlapping mechanisms, resistance and toxicity. The national or network protocol is the prescribing source because small differences in route, day, sequence and supportive care are clinically important.

Safe SACT delivery uses protocol matching, independent verification and prospective review before each cycle. Full blood count and organ function determine whether treatment proceeds, is delayed or modified. Previous toxicity, infection, performance status, body-weight change and interacting medicines matter as much as a threshold result. Central access, vesicant status and infusion-reaction precautions are checked before administration.

Toxicity continues after discharge. Patients need a thermometer where appropriate, immediate contact instructions and clarity that fever, shivering, breathlessness, diarrhoea or sudden illness must not wait for routine review. Acute oncology should receive regimen, cycle day, expected nadir and prophylaxis. After treatment, surveillance includes late cardiac, pulmonary, renal, neurological, fertility and second-malignancy effects according to exposure.

Indications, selection and cautions

Expected myelosuppression

Neutrophils, platelets and haemoglobin may fall at a regimen-specific time, requiring trends and clinical assessment before redosing.

Neutropenic sepsisRed flag

Fever, shivering, hypotension, confusion or unexplained deterioration after treatment needs immediate emergency antibiotics and sepsis care.

Infusion reaction

Flushing, urticaria, wheeze, chest discomfort, hypotension or back pain during infusion requires stopping administration and emergency assessment.

Dose-limiting organ toxicity

Neuropathy, mucositis, diarrhoea, renal decline, hepatic injury or cardiopulmonary symptoms can require delay, reduction or discontinuation.

ExtravasationRed flag

Pain, swelling, erythema, resistance or absent blood return during vesicant infusion requires immediate stop and agent-specific management.

Assessment before treatment

  1. 01
    Full blood count before each cycleFirst step
    Why
    Confirm marrow recovery and detect anaemia or thrombocytopenia.
    Interpretation and limitations
    Apply the exact regimen threshold and trajectory; unexpected pancytopenia also prompts infection, bleeding, marrow or medicine review.
  2. 02
    Renal and hepatic profile
    Why
    Determine clearance, organ toxicity and dose eligibility.
    Interpretation and limitations
    Use current protocol calculations and relevant baseline value; small creatinine changes can materially alter exposure for selected agents.
  3. 03
    Baseline agent-specific assessment
    Why
    Measure vulnerable organ reserve before exposure.
    Interpretation and limitations
    Depending on regimen this may include echocardiography, lung function, hearing, neuropathy, viral screening, pregnancy or pharmacogenomic testing.
  4. 04
    Cultures and lactate in suspected sepsis
    Why
    Identify infection and physiological severity without delaying antibiotics.
    Interpretation and limitations
    Take blood cultures including central-line samples promptly, but give empirical intravenous antibiotics within the emergency pathway.
  5. 05
    Toxicity grading and medication review

Treatment approach

01AuthoriseVerify every treatment cycleFirst stepA patient attends for protocol-based cytotoxic treatment.+
  1. 1Confirm identity, diagnosis, intent, consent, regimen, cycle, body size or renal calculation, allergies and previous dose modifications.
  2. 2Review performance, infection, toxicity, full blood count, renal, hepatic and agent-specific results against the current protocol.
  3. 3Authorise, delay, reduce or stop with documented rationale and independent pharmacy and administration checks; prescribe supportive care concurrently.
02DeliverAdminister through the correct routeThe cycle is authorised and prepared.+
  1. 1Confirm medicine, dose, sequence, route, access patency, vesicant precautions and premedication immediately before administration.
  2. 2Observe for infusion reaction and

Regimens, contraindications and interactions

Illustrates that an oral fluoropyrimidine is still SACT requiring exact indication, cycle, independent verification, adherence review and emergency access.

Capecitabine (oral cytotoxic example)

A licensed monotherapy schedule is 1,250 mg/m² orally twice daily on days 1–14 of a 21-day cycle, taken within 30 minutes after food; combination protocols commonly use different starting doses. Calculate each dose and apply protocol, renal and toxicity modifications rather than copying this example.

Check dihydropyrimidine dehydrogenase status before treatment. Diarrhoea, mucositis, hand-foot syndrome, marrow suppression and cardiotoxicity require prompt holds; severe renal impairment is contraindicated and major interactions include coumarin anticoagulants.

NICE-recommended initial intravenous beta-lactam monotherapy for suspected neutropenic sepsis unless contraindicated by patient factors or local resistance patterns.

Piperacillin/tazobactam for suspected neutropenic sepsis

Give the first adult dose 4.5 g intravenously immediately; the licensed febrile-neutropenia schedule is 4.5 g every 6 hours, then modify to local microbiology, allergy, prior resistance, cultures and renal function. Do not add an aminoglycoside or glycopeptide routinely without a patient-specific or local indication.

Complications, monitoring and follow-up

  • Before each cycle trend blood count, renal and hepatic function, weight, performance status, infection and cumulative toxicity against protocol.
  • During infusion observe access, vital signs and agent-specific reactions, documenting total dose and any interruption accurately.
  • Between cycles use a 24-hour treatment line and capture emergency attendance, antimicrobials, diarrhoea, vomiting, mucositis, bleeding and adherence.
  • Reassess radiological and clinical response at the planned decision point rather than continuing a tolerated but ineffective regimen automatically.
  • After completion monitor exposure-specific late cardiac, pulmonary, renal, neurological, endocrine, fertility and second-cancer risks.

Special situations

Protocol is the prescription

A familiar drug name is insufficient because sequence, route, infusion time, supportive care and organ rules differ between regimens.

Nadir is not reassurance

A patient can develop sepsis before the expected lowest count, and clinical deterioration demands action regardless of calendar day.

Cumulative toxicity matters

Neuropathy, cardiac exposure and marrow injury can worsen cycle by cycle even when each individual administration appears tolerated.

Supportive care is treatment

Antiemesis, hydration, prophylaxis and emergency education determine whether intended dose and quality of life can be maintained.

Intent changes trade-offs

A toxicity accepted for realistic cure may be inappropriate for minimal palliative benefit; consent must make intent explicit.

Common pitfalls

  1. 01

    Copying the previous cycle without fresh review.

  2. 02

    Waiting for neutrophil results before sepsis antibiotics.

  3. 03

    Ignoring route, sequence or vesicant status.

  4. 04

    Forgetting cumulative and late toxicity.

  5. 05

    Prescribing cytotoxic treatment without supportive medicines.

  6. 06

    Continuing ineffective treatment because toxicity is acceptable.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Oncology and palliative careOriginal SBA

Fever after chemotherapy

A patient receiving cytotoxic chemotherapy reports rigors and feels faint, but the current neutrophil count is not yet available. What is the priority?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Oncology and palliative care topics →
Sources and review status9 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG151 neutropenic sepsis recommendationsRecognition, immediate empirical antibiotics and inpatient risk assessment after anticancer treatment.
  • NHS England adult cancer chemotherapy service specificationCurrent requirements for safe, protocol-governed systemic anticancer treatment services.
  • NHS England cancer programmeAcute oncology access and coordinated delivery of systemic cancer treatment.
  • NICE shared decision making recommendationsCommunication of treatment intent, benefit, toxicity and alternatives.
  • UKONS acute oncology initial management guidelinesImmediate assessment and a door-to-needle target within 1 hour for suspected neutropenic sepsis.
  • BOPA cancer-medicine prescription verification standards2025 independent verification standards for regimen, cycle, calculations, results and dose modifications.
  • Piperacillin/tazobactam Summary of Product CharacteristicsAdult febrile-neutropenia dose, renal adjustment and medicine safety information.

Key points

  • Cytotoxic medicines damage dividing cells through DNA injury, antimetabolite action, mitotic disruption or topoisomerase effects; combinations attack different vulnerabilities but compound toxicity.
  • Regimen choice depends on histology, stage, intent, biomarkers, prior therapy, organ function and patient goals; the protocol specifies medicines, sequence, cycle and modifications.
  • Before every cycle verify identity, consent, intent, performance, blood count, renal and hepatic function, toxicity, infection and dose changes through an independent SACT process.
  • Dosing may use body surface area, weight, renal function or exposure-based calculation; never reconstruct a regimen from memory or copy a previous cycle blindly.
  • Myelosuppression, mucositis, nausea, diarrhoea, alopecia, infertility and fatigue are common, while individual agents add cardiac, renal, pulmonary, neurological or bladder toxicity.
  • Supportive antiemetics, growth-factor prophylaxis, hydration and infection prevention are regimen-specific and should be prescribed with the anticancer medicines.
  • Suspected neutropenic sepsis is an acute medical emergency: assess and culture without delaying the first empirical antibiotic, aiming to administer it within 1 hour of acute presentation; a normal temperature or pending blood count does not make deterioration safe.
Why
Convert patient symptoms and interactions into a cycle decision.
Interpretation and limitations
Grade does not replace judgement; cumulative and quality-of-life effects can be significant before a nominal severe category.
extravasation
, stopping the drug while maintaining access if either is suspected and following the agent-specific kit.
  • 3Provide written cycle dates, expected nadir, supportive medicines, 24-hour contact and emergency symptoms before discharge.
    • 03RescueTreat acute toxicityFever, deterioration, severe gastrointestinal loss, organ symptoms or infusion injury occurs.+
    1. 1Use ABCDE assessment, contact acute oncology, identify the regimen and cycle day, and obtain urgent blood count, organ profile, lactate and cultures as indicated.
    2. 2Give the first empirical neutropenic-sepsis antibiotic immediately and target administration within 1 hour of acute presentation, while resuscitating shock and treating anaphylaxis or other organ emergencies without awaiting oncology review.
    3. 3Record the event, reconcile causality and prophylaxis, and require specialist reassessment before any further cycle.

    Take cultures without delaying treatment, verify severe beta-lactam allergy, adjust for renal impairment, review sodium load and monitor blood count, kidney, liver and microbiology. Escalate shock and source control in parallel.

    Shortens neutropenia and reduces febrile-neutropenia risk when primary or secondary prophylaxis is indicated by regimen and patient risk.

    Filgrastim for protocol-defined neutropenia prophylaxis

    A usual cytotoxic-chemotherapy dose is 5 micrograms/kg subcutaneously once daily, started at least 24 hours after chemotherapy and continued until the expected neutrophil nadir has passed and recovery is sustained; follow the regimen and product-specific duration.

    It does not treat sepsis or replace immediate antibiotics. Bone pain is common; monitor blood count and consider rare splenic rupture, acute respiratory distress, capillary leak, aortitis and sickle-cell complications.

    Capecitabine Summary of Product Characteristics
    Licensed schedules, DPD testing, renal restrictions, interaction and toxicity information.
  • Filgrastim Summary of Product CharacteristicsUsual cytotoxic-chemotherapy dose, timing, duration and important adverse effects.

    • Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

    Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
    Provide a 24-hour treatment line, written warning symptoms, reproductive advice and a medication-interaction plan before the first dose.